İbrahim Barışta

Prognostic significance of <i>MYC</i>, <i>BCL2</i>, and <i>BCL6</i> rearrangements in patients with diffuse large B‐cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab

Nalân Akyürek, Ayşegül Üner, Mustafa Beneklı et al. · Cancer · 2011 · 158 citations · Full text

Early and Late Arrhythmogenic Effects of Doxorubicin

İbrahim Barışta, Kudret Aytemir, Sercan Aksoy et al. · Southern Medical Journal · 2007 · 122 citations

Risk Factor Assessment and Prognosis of Eye Involvement in Behçet's Disease in Turkey

Halûk Demiroğlu, İbrahim Barışta, Semra Dündar · Ophthalmology · 1997 · 95 citations

Ocular Disease, Autoimmune Disease, Ophthalmology +6

European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte‐predominant Hodgkin disease

Richard B. Wilder, Pamela J. Schlembach, Dan Jones et al. · Cancer · 2002 · 68 citations · Full text

Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

Hüseyin Saffet Beköz, Nuri Karadurmuş, S. Paydaş et al. · Annals of Oncology · 2017 · 68 citations · Full text